Tests Improved for Detection of Helicobacter Pylori Antigen
|
By LabMedica International staff writers Posted on 28 Oct 2009 |
Tests for the of Helicobacter pylori antigen in stool samples have been improved. These tests can be used for the diagnosis and management of active H. pylori infection.
Employing a combination of amplification technology and monoclonal antibodies, two noninvasive tests can be performed using a patient stool sample. They detect H. pylori antigen with a high degree of accuracy and can be used to diagnose current infection in both adult and pediatric patients. Unlike serology methods, these stool antigen tests can be used to detect active infection and to confirm the eradication of H. pylori following antibiotic therapy.
A rapid immunochromatographic membrane-based assay provides reliable results in just 15 minutes, without the need for special equipment. Called Rapid Hp StAR, the method is suitable for small volume testing in the laboratory or for near patient testing in gastroenterology clinics and doctors offices. This makes it convenient for monitoring the efficacy of antimicrobial treatment without the need for return hospital visits.
The second test, IDEIA Hp StAR, is a sensitive and specific enzyme immunoassay. The test is easy to perform using standard equipment, allowing the "test and treat” policy recommended by the European Helicobacter Study Group (EHSG) to be implemented in routine laboratories. It is suitable for both manual and automated testing and has demonstrated good performance when compared to the urea breath test and alternative enzyme immunoassays.
The two tests are produced by Oxoid (Basingstoke, UK), a microbiology company whose products are used in laboratories to help diagnose infectious diseases. Laura Ward, marketing manager, Oxoid commented, "The Hp StAR tests provide cost effective, noninvasive alternatives to the more invasive methods offered by many hospitals. They involve minimal discomfort for the patient, making them particularly suitable for pediatric use. Furthermore, the ability to detect active infections also helps to avoid the unnecessary administration of antibiotics."
Oxoid is part of Thermo Fisher Scientific Inc. (Waltham MA, USA). Thermo Scientific offers analytical instruments as well as laboratory equipment, software, services, consumables, and reagents to enable integrated laboratory workflow solutions. Fisher Scientific has a portfolio of laboratory equipment, chemicals, supplies, and services used in healthcare, scientific research, safety, and education.
Related Links:
Oxoid
Thermo Fisher Scientific Inc.
Employing a combination of amplification technology and monoclonal antibodies, two noninvasive tests can be performed using a patient stool sample. They detect H. pylori antigen with a high degree of accuracy and can be used to diagnose current infection in both adult and pediatric patients. Unlike serology methods, these stool antigen tests can be used to detect active infection and to confirm the eradication of H. pylori following antibiotic therapy.
A rapid immunochromatographic membrane-based assay provides reliable results in just 15 minutes, without the need for special equipment. Called Rapid Hp StAR, the method is suitable for small volume testing in the laboratory or for near patient testing in gastroenterology clinics and doctors offices. This makes it convenient for monitoring the efficacy of antimicrobial treatment without the need for return hospital visits.
The second test, IDEIA Hp StAR, is a sensitive and specific enzyme immunoassay. The test is easy to perform using standard equipment, allowing the "test and treat” policy recommended by the European Helicobacter Study Group (EHSG) to be implemented in routine laboratories. It is suitable for both manual and automated testing and has demonstrated good performance when compared to the urea breath test and alternative enzyme immunoassays.
The two tests are produced by Oxoid (Basingstoke, UK), a microbiology company whose products are used in laboratories to help diagnose infectious diseases. Laura Ward, marketing manager, Oxoid commented, "The Hp StAR tests provide cost effective, noninvasive alternatives to the more invasive methods offered by many hospitals. They involve minimal discomfort for the patient, making them particularly suitable for pediatric use. Furthermore, the ability to detect active infections also helps to avoid the unnecessary administration of antibiotics."
Oxoid is part of Thermo Fisher Scientific Inc. (Waltham MA, USA). Thermo Scientific offers analytical instruments as well as laboratory equipment, software, services, consumables, and reagents to enable integrated laboratory workflow solutions. Fisher Scientific has a portfolio of laboratory equipment, chemicals, supplies, and services used in healthcare, scientific research, safety, and education.
Related Links:
Oxoid
Thermo Fisher Scientific Inc.
Latest Immunology News
- Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
- Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
- Study Points to Autoimmune Pathway Behind Long COVID Symptoms
- Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
- Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
- Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
- Biomarkers and Molecular Testing Advance Precision Allergy Care
- Point-of-Care Tests Could Expand Access to Mpox Diagnosis
- T-Cell Senescence Profiling May Predict CAR T Responses
- Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care
- Study Highlights Low Sensitivity of Current Lyme Tests in Early Infection
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








